Intellikine LLC

Ambrx, Inc.

Other

University of California

Infinity Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Itellikine LLC

Takeda Pharmaceutical Company Limited

Troy Edward Wilson

Yi Liu

Pingda Ren

Liansheng Li

Katrina Chan

Christian Rommel

Ho Sung Cho

Thomas O Daniel

Anna-Maria A Hays

David C Litzinger

Richard Dennis DiMarchi

Bee-Cheng Sim

Simon F Campbell

Bruce E Kimmel

Alfredo C Castro

Catherine Anne Evans

Feng Tian

Daniel A Snyder

Michael Martin

Thomas P Cujec

Lillian Ho

Lynne Bui

Kevan M Shokat

Anna-Maria A Hays Putnam

Andrew Gaheem Hsieh

Roberto Mariani

William M Keefe

Katayoun Jessen

Xin Guo

Mark D Bednarski

Davide Ruggero

Beth Apsel

Matthew Janes

David Pearce

Morris Feldman

David Fruman

Mark S Mastandra

Richard D Dimarchi

Simon Fraser Campbell

Anna Maria Hays Putnam

Anna-Maria Hays

Richard Dimarchi

Thomas Daniel

A turf removal attachment is bolted to a skid steer to allow hydraulic motors thereon to first power cutting blades to form easily removable strips of turf and then, on a lower gear ratio, the drum to which roller tines are attached to spool the strips of turf. Hydraulic circuitry is provided to permit the hydraulic fluid of the skid steer to power the turf removal tools on the turf removal attachment.

Method of removing synthetic turf and synthetic turf removal attachment

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Heterocyclic compounds and uses thereof

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

Certain chemical entities, compositions and methods

Synthetic turf removal skid steer attachment assembly

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Kinase inhibitors and methods of use

Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.

Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity. 

Heterocyclic kinase inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

Enhanced treatment regimens using mTOR inhibitors

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

Benzothiazole kinase inhibitors and methods of use

The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.

MTOR modulators and uses thereof

The invention provides water-soluble compounds that include a polymer and at least one terminal azide or acetylene moiety. Also provided are highly efficient methods for the selective modification of proteins with PEG derivatives, which involves the selective incorporation of non-genetically encoded amino acids, e.g., those amino acids containing an azide or acetylene moiety, into proteins in response to a selector codon and the subsequent modification of those amino acids with a suitably reactive PEG derivative.

Polymer derivatives

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R, R, W, W, W, W, W, W, W, W, Wand Ware defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.

Substituted benzimidazoles as PI3 kinase inhibitors

Growing community of inventors

San Marino, CA, United States of America

Troy Edward Wilson